Koios Medical

Koios Medical is a healthcare technology company that develops artificial intelligence (AI)-powered software for early cancer diagnosis using ultrasound imaging. The company's flagship product, Koios DS, is an AI-based software platform that analyzes ultrasound images to accurately diagnose thyroid and breast cancers. Cleared by the US Food and Drug Administration in December 2021 and CE-marked in the EU in December 2022, Koios DS leverages computer vision and machine learning algorithms to automate interpretation, scoring, and reporting of ultrasound exams.

The software aids physicians in quickly and accurately diagnosing disease, improves speed of interpretation, automates reporting, and reduces time to treatment while avoiding unnecessary surgical procedures. Clinical studies showed Koios DS increased thyroid cancer detection rates by up to 14% while simultaneously reducing false positive biopsy orders by over 35%. Interpretation time per case dropped by over 24%, and variability was lowered by over 50%. The patented software aligns AI-generated findings directly to standard reporting systems like the Royal College of Radiology U1-U5 and ACR TI-RADS.

Koios DS is compatible with any PACS workstation viewer and integrated into GE healthcare's ultrasound scanners. The system enables real-time decision-making, with results exportable directly into a patient's record and all major reporting systems. In the US, breast and thyroid cancers combine for over 375,000 diagnosed cases annually, with over 2.2 million biopsy procedures performed yearly, highlighting the significant market opportunity for Koios Medical's AI-powered solutions.

Key customers and partnerships

Koios Medical has established partnerships with healthcare providers and organizations to expand access to its AI-enabled software for early cancer detection and diagnosis. In February 2023, Mitsui & Co., a leading Japanese conglomerate, participated as a lead investor in Koios Medical's Series B financing round. This strategic partnership aims to revolutionize medical imaging and empower clinicians worldwide with cutting-edge, life-saving technology.

Mitsui's investment facilitates collaborations between Koios Medical and Mitsui's existing healthcare portfolio companies, including IHH healthcare Berhad, a leading premium healthcare provider operating 80 hospitals across 10 countries. The partnership aligns with Mitsui's goal of transforming patient care by harnessing the potential of healthcare data and exploring innovative technological solutions.